drug
Vyvanse
Marketedupdated 5mo agoby $TAK TAKEDA PHARMACEUTICAL CO LTD
Approvedannual revenue · 2024–2024peak $1.5B
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Vyvanse
- phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
- phase1A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
- phase1A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
- phase4Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
- phase1To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.
- —A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
- phase4Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
News(2)
- Chutes & Ladders—Longtime Takeda R&D chief to depart next JuneTakeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.fiercebiotech · 23d ago
- Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successesAndy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.fiercebiotech · 24d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that